Longboard Pharmaceuticals
San Diego
About Longboard Pharmaceuticals
Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $79.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jan 2024)
- Ticker: nasdaq:LBPH
- Website: longboardpharma.com
- Phone: (619) 592-9775
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/longboard-pharmaceuticals-52498 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.